Women’s Health

Bacterial vaginosis (BV) is a type of vaginal inflammation that occurs when there is an imbalance or depletion of the normal vaginal flora, allowing for other pathogens to begin to grow.

The normal vaginal flora is dynamic and usually inhabited by lactobacilli, which keep it acidic and maintain a protected environment for the human host.

Women in their reproductive years are most likely to get Bacterial Vaginosis, but it can affect women of any age.

BV may increase the risk of sexually transmitted infections and cause serious pregnancy complications, including miscarriage and pre-term birth. Traditional therapy for symptomatic BV has been metronidazole. However, recent studies have shown that recurrent bacterial vaginosis after antimicrobial therapy is a major problem, affecting >50% of patients within one year. Providers are currently in need of a diagnostic tool to not only quickly identify pathogens that cause BV, but also monitor therapy success.

Core has developed an advanced molecular panel that specifically targets Bacterial Vaginosis, Candidiasis and Sexually Transmitted Infections (STIs).

According to Sobel et al, testing with qPCR may be a good prognostic tool immediately post treatment to assess for dominance among the vaginal species. The eradication of non-Lactobacilli species and return of Lactobacilli suggests better long-term treatment success with a decreased rate of recurrent BV.

• Prevents Delays in Diagnosis & Treatment
• Detects Polymicrobial Infections Simultaneously
• Unaffected by Concomitant Medications
• Reduces Unnecessary Drug Exposure and Adverse Events
• Decreases the Progression and Spread of Infection
• Improves Selection of Narrow-Spectrum Antibiotics